Sang-Jun Ha
Overview
Explore the profile of Sang-Jun Ha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
5630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yun J, Shin E, Lee Y, Lee J, Lee H, Kim J, et al.
Front Microbiol
. 2025 Feb;
16:1492268.
PMID: 39927262
Introduction: The inadequate efficacy of the Bacillus Calmette-Guérin (BCG) vaccine against adult pulmonary tuberculosis (TB) necessitates the development of new and effective vaccines. Human adenovirus serotype 5 (Ad5), which induces...
2.
Nguyen D, You S, Ngo H, Van Nguyen K, Tran K, Chu T, et al.
Nat Commun
. 2025 Jan;
16(1):1084.
PMID: 39870640
No abstract available.
3.
Park S, Ju S, Lee J, Kim H, Sub Y, Park D, et al.
Sci Adv
. 2025 Jan;
11(4):eadq2395.
PMID: 39841821
Until now, Hippo pathway-mediated nucleocytoplasmic translocation has been considered the primary mechanism by which yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) transcriptional coactivators regulate cell proliferation and...
4.
Kim C, Park D, Ahn B, Baek S, Hong M, Nguyen L, et al.
Nat Commun
. 2024 Dec;
15(1):10726.
PMID: 39730328
Immune checkpoint blockade (ICB) has become a standard anti-cancer treatment, offering durable clinical benefits. However, the limited response rate of ICB necessitates biomarkers to predict and modulate the efficacy of...
5.
Yun J, Kim A, Kim S, Shin E, Ha S, Kim D, et al.
Front Immunol
. 2024 Dec;
15:1474346.
PMID: 39624097
As Bacille Calmette-Guérin (BCG) vaccine's effectiveness is limited to only children, the development of new tuberculosis (TB) vaccines is being studied using several platforms, and a novel TB vaccine that...
6.
Kim N, Kim C, Ma J, Yang S, Park D, Ha S, et al.
Gut Microbes
. 2024 Sep;
16(1):2393791.
PMID: 39230075
Mouse gut microbiome research is pivotal for understanding the human gut microbiome, providing insights into disease modeling, host-microbe interactions, and the dietary influence on the gut microbiome. To enhance the...
7.
Im S, Lee K, Ha S
Exp Mol Med
. 2024 Sep;
56(9):1900-1908.
PMID: 39218982
IL-2 therapy, which enhances the function of CD8 + T cells, was initially employed as the cornerstone of immunotherapy against cancer. However, the impact of this therapy extends beyond CD8 ...
8.
Kim N, Kim C, Ma J, Yang S, Park D, Ha S, et al.
bioRxiv
. 2024 Aug;
PMID: 39211244
Mouse gut microbiome research is pivotal for understanding the human gut microbiome, providing insights into disease modeling, host-microbe interactions, and the dietary influence on the gut microbiome. To enhance the...
9.
Nguyen D, You S, Ngo H, Van Nguyen K, Tran K, Chu T, et al.
Nat Commun
. 2024 Aug;
15(1):6680.
PMID: 39107284
Synergistic combinations of immunotherapeutic agents can improve the performance of anti-cancer therapies but may lead to immune-mediated adverse effects. These side-effects can be overcome by using a tumor-specific delivery system....
10.
Lee S, Hong K, Park H, Ha J, Lee S, Park D, et al.
J Control Release
. 2024 Jul;
373:55-69.
PMID: 38971428
Immunogenic cell death (ICD) holds the potential for in situ tumor vaccination while concurrently eradicating tumors and stimulating adaptive immunity. Most ICD inducers, however, elicit insufficient immune responses due to...